|
| Code | Diagnosis | Comment | Score |
| anonymous | Malignant tumour (100%) | Malignant tumour, likely metastatsis, has to correlate with previous tumour site and morphology for definitive diagnosis. Differential diagnoses include Wilm's tumour, synovial sarcoma, need to exclude germ cell tumour such as yolk sac tumour. | 50 |
| anonymous | pleuropulmonary blastoma | nil | 50 |
| anonymous | Metastatic malignant neoplasm; DDx rhabdoid tumour (50%), rhabdomyosarcoma (50%) | Panel of IHC stains: muscle specific actin, desmin, myoD1, cytokeratin, EMA, S100. EM: tangled intermediate filaments (in rhabdoid tumour) | 80 |
| anonymous | Metastatic malignant spindle cell tumor (100%), differential diagnoses are rhabdomyosarcoma (10%), rhabdoid tumor(80%), PNET(3%), malignant peripheral nerve sheath tumor(4%), neuroblastoma (3%). | Review previous paraspinal tumor; Immunostaining : myoid markers (myogenin, desmin, actin) for rhabdomyosarcoma; cytokeratins for rhabdoid tumor, loss of INI1 in rhabdoid tumor, CD99 for PNET, S100, neuronal markers for neurogenic tumor. | 100 |
| anonymous | Malignant tumor consistent with metastases. Favor a sarcoma as primary. 100%. The differential includes 1)Rhabdomyosarcoma 2)Leiomyosarcoma 3)Germ cell tumor 4)Neuroblastoma 5)Melanoma. | Do immunostains eg. Myo-D1, desmin, AFP, S100 etc | 50 |
| anonymous | Malignant neoplasm. DDx among neuroblastoma, rhabdoid tumor( including atypical teratoid/rhabdoid tumor), rhabdomyosarcoma, and Wilm's tumor. | Do neuron specific enolase, synaptophysin, chromogranin, neurofilament and NB84 which will be positive in neuroblastoma. Do EMA, vimentin and smooth muscle actin which will be mostly positive in ATRT. Also negative stain for INI1. Do myogenin which will be positive for rhabdomyosarcoma. Do WT1 which will be positive in Wilm's tumor. | 60 |
| anonymous | Lung - metastatic sarcoma (rhabdomyosarcoma 40%, malignant rhabdoid tumor 40%, anaplastic Wilm's tumour 20%) | To review and correlate with previous paraspinal pathology. To apply immunostaining to assist in tumour classification. | 70 |
| anonymous | Metastatic malignant tumour DDx: Wilm's tumour & rhabdomyosarcoma | nil | 50 |
| anonymous | METASTATIC MALIGNANT TUMOUR 100% DDX RHABDOMYOSARCOMA, PERIPHERAL NERVE SHEATH TUMOUR | SUGGEST IMMUNOHISTOCHEMICAL STUDY IE MYOGENIN, MYOD1, DESMIN, S100 PROTEIN | 50 |
| anonymous | Metastatic sarcomatous lesion. Differential diagnosis: - Rhabdomyosarcoma; - Synovial sarcoma. | Immunohistochemistry to differentiate especially myogenin, desmin, EMA, ect. | 50 |
| anonymous | Lung mass, excision - Malignant tumor, favour metastatic sarcoma. Differential diagnosis includes metastatic poorly differentiated sarcoma, clear cell sarcoma of kidney and paraganglioma. | nil | 50 |
| anonymous | High grade malignant tumor (likely metastatic) | There are areas of apparent biphasic epithelioid-spindle cell pattern and some rhabdoid cytomorphology. Differential diagnoses include synovial sarcoma, rhabdoid tumor, pleuropulmonary blastoma and primitive neuroectodermal tumor etc. Suggest correlation with histology, immunohistochemistry, molecular studies and radiological findings of the lung and paraspinal masses. | 60 |
| anonymous | Malignant tumour, favour rhabdomyosarcoma. Perform staining for desmin, myoD1 and actin (100% probability) | nil | 50 |
| anonymous | High-grade sarcoma, differential diagnoses 1. Metastatic synovial sarcoma (50%) 2. Metastatic malignant peripheral nerve sheath tumour with glandular differentiation (30%) 3. Metastatic Wilm’s tumour (10%) 4. Metastatic Ewing’s tumour/PNET (10%) | 1. Perform immunostains for differentiation: Synovial sarcoma positive for EMA, bcl-2, CD99; MPNST positive for S100, Wilm’s tumour positive for WT1 and PNET positive for chromogranin and synaptophysin. 2. Retrieve old slides for assessment. | 50 |
| anonymous | Malignant biphasic tumour. Metastatic nephroblastoma (50%). Poorly differentiated synovial sarcoma (50%). | Immunohistochemical stain for EMA, Cam5.2, CD99 and bcl-2. RT-PCR for SYT-SSX translocation. | 50 |